Obesity Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer

Obesity Pipeline constitutes 80+ key companies continuously working towards developing 100+ Obesity treatment therapies, analyzes DelveInsight.

Obesity Overview:

**Obesity** refers to the **abnormal or excessive buildup of body fat** that negatively impacts health and increases the risk of conditions such as **type 2 diabetes, cardiovascular disease, hypertension**, and **high cholesterol**. It has become a major **public health crisis**, worsening steadily over the past five decades.

This **complex and multifactorial condition** ranks as the **second leading cause of preventable death**, following smoking. Research shows that even a **modest weight loss of 5-10%** can lead to marked improvements in health outcomes, quality of life, and reduce healthcare costs on both individual and societal levels.

Obesity arises primarily from an **imbalance between energy intake and expenditure**, leading to excess weight gain. While lifestyle plays a major role, obesity is also influenced by **genetic predispositions**, **cultural norms**, and **social environments**. Studies confirm that obesity is **highly heritable**, with numerous genes linked to increased body fat and weight gain.

Additional contributing factors include **sedentary behavior**, **sleep disturbances**, **hormonal disorders**, certain **medications**, and the widespread availability of **high-calorie, high-sugar foods**, as well as **reduced metabolic efficiency**.

Download our report @ https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Obesity Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Obesity Therapeutics Market.

Key Takeaways from the Obesity Pipeline Report

DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment.
In March 2024, the FDA approved Wegovy for an additional indication-to reduce the risk of major cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with known heart disease who are overweight or have obesity. This approval underscores the drug's benefits beyond weight management.
Key Obesity companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others are evaluating new drugs for Obesity to improve the treatment landscape.
Promising Obesity pipeline therapies in various stages of development include Survodutide, Ecnoglutide, CT-868, DD01, and others.

Obesity Pipeline Analysis
The Obesity pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Obesity Market.

Categorizes Obesity therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Obesity drugs under development based on:

Stage of development

Obesity Route of administration

Target receptor

Monotherapy vs. combination therapy

Obesity Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Obesity Licensing agreements

Funding and investment activities supporting future Obesity market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Obesity Emerging Drugs

Survodutide: Zealand Pharma
Ecnoglutide: Sciwind Biosciences
CT-868: Carmot Therapeutics
DD01: D&D Pharmatech

Obesity Companies

There are approximately 80 or more prominent companies actively working on developing therapies for obesity. Among them, Zealand Pharma stands out as one of the leading firms with an obesity drug candidate currently in Phase III, the most advanced stage of clinical development.

DelveInsight's report covers around 100+ products under different phases of Obesity clinical trials like

Obesity Late stage Therapies (Phase III)
Obesity Mid-stage Therapies (Phase II)
Obesity Early-stage Therapies (Phase I)
Obesity Pre-clinical and Obesity Discovery stage Therapies
Obesity Discontinued & Inactive Therapies

Obesity pipeline report provides the Obesity therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Obesity Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Obesity Therapies and Key Obesity Companies: Obesity Clinical Trials and recent advancements https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Obesity Pipeline Therapeutic Assessment
• Obesity Assessment by Product Type
• Obesity By Stage
• Obesity Assessment by Route of Administration
• Obesity Assessment by Molecule Type

Download Obesity Sample report to know in detail about the Obesity treatment market @ Obesity Therapeutic Assessment https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Obesity Current Treatment Patterns
4. Obesity - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Obesity Late-Stage Products (Phase-III)
7. Obesity Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Obesity Discontinued Products
13. Obesity Product Profiles
14. Obesity Key Companies
15. Obesity Key Products
16. Dormant and Discontinued Products
17. Obesity Unmet Needs
18. Obesity Future Perspectives
19. Obesity Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Obesity Pipeline Reports Offerings: https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.